| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Lisaftoclax (APG-2575) Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with Lisaftoclax in a pivotal Phase 2 study | Phase 2 | — | Small Molecules | Oncology | ||
Phase 2 data readout example | Lisaftoclax (APG-2575) Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with Lisaftoclax in a pivotal Phase 2 study | Phase 2 | — | Small Molecules | Oncology | ||
Phase 2 data readout example | Lisaftoclax (APG-2575) Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with Lisaftoclax in a pivotal Phase 2 study | Phase 2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Ascentage Pharma Group International - American Depository Shares$17.6
+0.49 (+2.86%)
C 54Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.97 B
EPS
-1.94
P/E Ratio
-
Value Trade
403.00 K
8.08 %
Week
-18.12 %
1 Month
-11.95 %
3 Month
-31.11 %
6 Month
21.8 %
5 Year
21.8 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
11.88 K
52 Week Range
18.56 - 48.45
% held by Insiders
-
% held by Institutions
0.03 %
Enterprise Value
1.90 B
Total Shares
92.95 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C54
Pipeline Score $793M
Pipeline ValueOvervalued
Valuation Signal14
Drugs Scored0.4x
rNPV / MCap Top 79%
Micro Cap (rank 191 of 905)
Percentile RankAscentage Pharma Group International - American Depository Shares carries a moderate pipeline score (54/100), with $2.3B risk-adjusted pipeline value, led by APG-115 in T-Prolymphocytic Leukemia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APG-115 Small molecule | Malignant Salivary Gland Cancer | Phase 2 | NCT03781986 | 10% | $406M | ACTIVE NOT_RECRUITING | 41 | - | - | Jan 1, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
olverembatinib | Philadelphia chromosome-positive acute lymphoblastic leukemia,myeloid/lymphoid neoplasm with FGFR1 rearrangement | Phase 2 | 2025-06-16 | |||
olverembatinib | Philadelphia chromosome-positive acute lymphoblastic leukemia,myeloid/lymphoid neoplasm with FGFR1 rearrangement | Phase 2 | 2025-06-16 | |||
olverembatinib | Philadelphia chromosome-positive acute lymphoblastic leukemia,myeloid/lymphoid neoplasm with FGFR1 rearrangement | Phase 2 | 2025-06-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AAPG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
AAPG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AAPG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AAPG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AAPG Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
AAPG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Ascentage Pharma Group International - American Depository Shares (AAPG) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How AAPG ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Cancer | #3 of 3 | Olverembatinib | GEHC ·dev ZBH ·dev | $28.1B | 0 | ||
| General Hematological Disorders | #4 of 4 | Lisaftoclax + Reduced-dose HHT + standard-dose HHT + Azacitidine + olverembatinib | VRTX LLY AZN | — | 0 | ||
| Anemia | #7 of 8 | APG-5918 | BMY AKBA TAK | $0.77B | 0 | ||
| Myelodysplastic Syndromes | #11 of 33 | Lisaftoclax + Azacitidine | BMY ABBV TAK | $2.5B | 0 | ||
| Mesothelioma | #15 of 15 | APG-2449 | AZN MRK NVS | $0.65B | 0 | ||
| Leukemia | #19 of 64 | Olverembatinib + Imatinib | AMGN LLY AZN | $4.28B | 0 | ||
| Sarcoma | #20 of 31 | APG-115 + Toripalimab | NVS INTS LLY | $1.75B | 0 | ||
| Systemic Lupus Erythematosus | #21 of 32 | APG-2575 | BIIB VTRS BMY | $2.78B | 0 | ||
| Lymphoma | #34 of 69 | APG-2575 + Rituximab + Ibrutinib | REGN LLY MRK | $8.52B | 0 | ||
| Melanoma | #36 of 52 | Phase 1b: APG-115+pembrolizumab | MRK BMY REGN | $10.5B | 0 | ||
| Esophageal Cancer | #38 of 39 | APG-2449 | MRK AZN ONC | $1.85B | 0 | ||
| Ovarian Cancer | #55 of 61 | APG-2449 | MRK AZN LLY | $4.0B | 0 | ||
| Non-Small Cell Lung Cancer | #83 of 88 | APG-2449 | MRK AMGN AZN | $28.1B | 0 |